Novo Preempts Earnings Reveal With Preview Of Wegovy-Driven Growth
Blockbuster Obesity Treatment To Face New Rival This Year
Novo Nordisk said sales increased 25% in the first quarter, driven by US demand for GLP-1 agonist Wegovy for obesity, and increased its 2023 sales growth guidance from a range of 13%-19% to 24%-30%.
